Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients.


Journal

NPJ primary care respiratory medicine
ISSN: 2055-1010
Titre abrégé: NPJ Prim Care Respir Med
Pays: England
ID NLM: 101631999

Informations de publication

Date de publication:
20 10 2020
Historique:
received: 02 07 2020
accepted: 23 09 2020
entrez: 21 10 2020
pubmed: 22 10 2020
medline: 2 9 2021
Statut: epublish

Résumé

This study reports the association of ICS use and the risk of type 2 diabetes mellitus (T2DM) in Swedish patients with COPD using data from real-world, primary care settings. A total of 7078 patients with COPD were included in this analysis and the 5-year cumulative incidence rate per 100,000 person years was 1506.9. The yearly incidence rate per 100,000 person years ranged from 850 to 1919. Use of ICS especially at a high dose in patients with COPD was related to an increased risk of T2DM.

Identifiants

pubmed: 33082331
doi: 10.1038/s41533-020-00207-7
pii: 10.1038/s41533-020-00207-7
pmc: PMC7576803
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Bronchodilator Agents 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

47

Références

Diabetes Care. 2004 Oct;27(10):2478-84
pubmed: 15451919
NPJ Prim Care Respir Med. 2018 Sep 10;28(1):33
pubmed: 30202023
Respiration. 2010;80(2):89-95
pubmed: 20501985
PLoS One. 2016 Sep 22;11(9):e0162903
pubmed: 27658209
Int J Chron Obstruct Pulmon Dis. 2018 Jan 11;13:275-285
pubmed: 29391785
Diabetes Obes Metab. 2020 Aug;22(8):1348-1356
pubmed: 32239604
Respir Med. 2012 Nov;106(11):1487-93
pubmed: 22902134
Eur Respir J. 2008 Oct;32(4):962-9
pubmed: 18579551
Eur Clin Respir J. 2017 Dec 04;4(1):1409060
pubmed: 29230274
Respir Res. 2018 Sep 10;19(1):172
pubmed: 30200965
Br J Clin Pharmacol. 2002 Jul;54(1):59-64
pubmed: 12100226
NPJ Prim Care Respir Med. 2019 Dec 10;29(1):45
pubmed: 31822681
NPJ Prim Care Respir Med. 2019 Oct 28;29(1):38
pubmed: 31659161
Am J Med. 2010 Nov;123(11):1001-6
pubmed: 20870201

Auteurs

Björn Ställberg (B)

Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden. b.stallberg@telia.com.

Christer Janson (C)

Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.

Karin Lisspers (K)

Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden.

Gunnar Johansson (G)

Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden.

Florian S Gutzwiller (FS)

Novartis Pharma AG, Basel, Switzerland.

Karen Mezzi (K)

Novartis Pharma AG, Basel, Switzerland.

Bine Kjoeller Bjerregaard (BK)

IQVIA Solutions, Copenhagen, Denmark.

Anne Mette Tranberg Kejs (AMT)

IQVIA Solutions, Copenhagen, Denmark.

Leif Jorgensen (L)

IQVIA Solutions, Copenhagen, Denmark.

Kjell Larsson (K)

Integrative Toxicology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH